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RatPrevious studies have demonstrated that chemical stimulation of the lateral hypothalamus (LH) with
carbachol has an important role in the induction of antinociception in tail-flick test as a model of acute
pain. In this study, we tried to evaluate the involvement of orexin-1 receptors in the ventral tegmental
area (VTA) and the nucleus accumbens (NAc) on antinociceptive responses induced by LH stimulation in
rats. One hundred twenty adult male albino Wistar rats weighing 200–250 g were unilaterally implanted
with two separate cannulae into the LH, and VTA or NAc. Antinociceptive effects for two doses of intra-LH
carbachol (125 and 250 nmol/0.5 μl saline), as a cholinergic agonist, were evaluated in this study. In another
set of experiments, animals received intra-VTA or -NAc infusions of SB334867 as a selective orexin-A receptor
antagonist (0.3, 1, 3 and 10 nmol/rat), just 5 min before microinjection of an effective dose of carbachol into
the LH. In the tail-flick test, antinociceptive responses of drugs were obtained by tail-flick analgesiometer and
represented as maximal possible effects (%MPE) at 5, 15, 30, 45 and 60 min after their administrations.
The results showed that unilateral intra-LH administration of carbachol (125 and 250 nmol/rat) induced
antinociception in rats (P b 0.01). There were no significant differences between the antinociceptive effects of
these two doses. In the second part of our study, intra-VTA and intra-accumbal administrations of different
doses of SB334867, 5 min beforemicroinjection of carbachol, could dose-dependently prevent the development
of LH stimulation-induced antinociception in rats. However, this effect was less in the NAc. It is supposed that the
orexinergic projections from the LH to the VTA and NAc are direct/indirectly involved in the antinociception
induced by LH chemical stimulation, and orexin-1 receptors in the ventral tegmental area have amore substantial
role in this phenomenon.
© 2013 Elsevier Inc. All rights reserved.1. Introduction
Our previous study has shown that the stimulation or inactivation
of lateral hypothalamus (LH) produces antinociception (Safari et al.,
2009). Several lines of evidence demonstrated that electrical and
chemical stimulation of the LH can lead to levels of antinociception
(Behbehani et al., 1988; Holden and Naleway, 2001). This area also
has an important role in the modulation of nociceptive transmission
at the level of the spinal cord (Aimone and Gebhart, 1987). One of
the most important neurotransmitters in the LH is orexin. In fact,
these neuropeptides are exclusively made in LH neurons that are
projected throughout the central nervous system (CNS) (Lu et al.,
2000; Marcus et al., 2001; Trivedi et al., 1998). Orexinergic projections
from the LH (Mondal et al., 1999; Nambu et al., 1999) are innervatedzhdari-Zarmehri),
rights reserved.the different areas in the CNS such as the ventral tegmental area
(VTA), nucleus accumbens (NAc), hippocampus and prefrontal cortex
(Fallon and Moore, 1978; Lindvall and Bjorklund, 1974).
The orexins (also known as hypocretin) are neuropeptides trans-
mitters that comprise of two distinct peptides called orexin-A and
orexin-B. These neuropeptides result from prepro-orexin molecule
during the proteolytic process (de lecea et al., 1998; Sakurai et al.,
1998) which then activate two groups of G-protein coupled receptors:
the orexin 1 (Ox1r) and 2 (Ox2r) receptors (Sakurai et al., 1998). Ox1r
is selective for orexin A whereas Ox2r is willing for both orexins A and
B (Sakurai et al., 1998). These neuropeptides are produced by
orexin-expressing neurons which are frequently located in the posterior
hypothalamus and extend to the dorsomedial and lateral hypothalamus
(Peyron et al., 1998). The orexinergic system is most strongly associated
with feeding, arousal, sleep, reward, addiction, stress, and pain processing
(Azhdari Zarmehri et al., 2011; Harris et al., 2005; Petrovich and
Gallagher, 2003; Safari et al., 2009; Sakurai et al., 1998; Sharf et al.,
2010; Taslimi et al., 2011). The LH is associated with many nuclei which
are effective in antinociception (Azhdari Zarmehri et al., 2011; Safari
et al., 2009). Furthermore, it has been shown that the hypothalamic
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brain regions, but most studies have focused on the VTA (Sharf et al.,
2010).
Based on previous reports in the VTA, the orexinergic projections
infrequently synapse onto dopamine (DA) and GABA neurons.
Nonetheless, these synapses have numerous dense orexin-containing
core vesicles suggesting non-synaptic effects (Balcita-pedicino and
Sesack, 2007). Both kinds of orexin receptors (Ox1r and Ox2r) have
been found at high density in the VTA (Lu et al., 2000; Narita et al.,
2006). In the VTA, orexins stimulate both DA and non-DA cells via a
direct postsynaptic effect. Orexin receptor activation in the VTA could
increase dopamine release via projecting neurons (Korotkova et al.,
2003; Nakamura et al., 2000) in theNAcwhich is an important neuronal
substrate of pain modulation (Breese et al., 1987).
The NAc is divided into the core and shell, and both of them directly
or indirectly receive projections from the VTA (Deutch and Cameron,
1992). It seems that the functional interaction between NAc and VTA
is implicated in pain processing, it is likely that the NAc is also involved
in nociception (Magnusson and Martin, 2002). Additionally, both Ox1r
and Ox2r have also been reported to be expressed in the NAc (Martin
et al., 2002). There are several reasons to believe that the analgesia
induced by substance P (SP), by the release of DA from terminals in
the NAc (Kalivas, 1985) and intra-VTA infusion of SP increase DA
metabolism in the NAc (Cador et al., 1989). Moreover, intra-VTA
infusions of μ-opioid receptor agonists stimulate locomotor activity
(Joyce et al., 1981: Kalivas et al., 1983; Latimer et al., 1987), and
intra-NAc DA receptor antagonists or lesions made to the NAc, block
this effect (Stinus et al., 1980; Kalivas et al., 1983). Therefore, considering
the studies mentioned above, in the present study, we tried to examine
the involvement of orexin-1 receptors within the VTA and NAc in
antinociception induced by LH stimulation by the tail-flick test as an
animal model of acute pain.
2. Materials & methods
2.1. Animals
One hundred twenty adult male albinoWistar rats (Pasteur Institute,
Tehran, Iran) weighing 200–250 g were used in these experiments.
The vivarium was maintained on a 12:12 h light/dark cycle at a room
controlled temperature (23 ± 1 °C) with free access to chow and tap
water. The animals were randomly allocated to different experimental
groups. Each animal was used only once. Rats were habituated to their
new environment and handled for 1 week before the experimental
procedure started. All experiments were executed in accordance with
theGuide for the Care andUse of Laboratory Animals (National Institutes
of Health Publication No. 80–23, revised 1996) and were approved
by the Research and Ethics Committee of Shahid Beheshti University of
Medical Sciences.
2.2. Stereotaxic surgery
Animals were unilaterally prepared with a guide cannula implanta-
tion at least 5–7 days before their use. The rats were anesthetized
with intraperitoneal (i.p.) injection of Ketamine 10% (100 mg/kg) and
Xylazine 2% (10 mg/kg) and cannulae were stereotaxically implanted
in the LH, and the NAc or VTA (Stoelting, USA). The coordinates for
these regions were determined by the rat brain atlas (Paxinos and
Watson, 2007), AP = 4.8 mmcaudal to bregma, Lat = ±0.9 mm lateral
tomidline, DV = 8.3 mm ventral from the skull surface for VTA (cannu-
la 23-gauge, 11 mm, guide cannula was 1 mm above the appropriate
injection place) and for the NAc (cannula 23-gauge, 11 mm ) was
AP = 1.7 ± 0.5 mm to bregma, Lat = ±1.6 mm lateral to midline,
DV = 7.8 mm ventral from the skull surface and for the LH
(cannula 23-gauge, 12 mm) was AP = 3 mm caudal to bregma,
Lat = +1.6 mm and DV = 8.8 mm ventral from the skull surface.The guide cannulae were secured in place using two stainless steel
screws anchored to the skull and dental acryl cement. After the cement
was completely dried and hardened, two stainless steel stylets were
used to occlude the guide cannulae during recovery period. Penicillin-
G 200,000 IU/ml (0.2–0.3 ml/rat, single dose, intramuscular) was
immediately administered after surgery. Animals were individually
housed and allowed to recover for 5–7 days before experiments.
2.3. Drugs
In the present study, carbachol (Sigma–Aldrich, USA) as a cholinergic
agonist was dissolved in physiological saline, and SB334867 (Tocris
Bioscience, Bristol, UK), OX1 receptor antagonist, was dissolved in
dimethyl sulfoxide (DMSO; Sigma–Aldrich, Germany). Control animals
received either saline or DMSO as vehicles. All drugs were freshly
prepared on the day of experiment.
2.4. Drug administration
Microinjections were performed by lowering a stainless steel
injector cannula (30-gauge needle) with a length of 1 mm longer
than the guide cannulae into the LH and VTA or NAc. The injector
cannula was connected to a 1-μl Hamilton syringe by polyethylene
tubing (PE-20), then drug solution or vehicle was unilaterally infused
over 60 s and was left for 60 s extra time and followed by replacement
of the obdurator. Different doses of carbachol were administered in a
total volume of 0.5 μl/rat over a period of 60 s into the LH, slowly.
SB334867 solutions (with DMSO as a vehicle) were administered in a
total volume of 0.3 and 0.5 μl over a period of 60 s into the VTA and
NAc, respectively. Injection needles were left in place for an additional
60 s to facilitate diffusion of the drugs, and then the stylets were
reinserted into the guide cannulae. All drug solutions were freshly
prepared on the test day, and all microinjections were unilaterally
performed.
2.5. Tail-flick test
The nociceptive threshold was measured by the tail-flick apparatus
(Harvard Apparatus, USA). Tail-flick test is an animal model of acute
pain. The heat was applied in succession after the 3, 5 and 7 cm from
the caudal tip of the tail. The value of each tail-flick latency (TFL) time
was calculated on the average of three consecutive TFL tests in each
time point. The reaction time between the onset of heat stimulus and
the movement of tail was determined by an automatic sensor as TFL.
The light source was set at an intensity that yields baseline TFL values
in the range of 3–4 s (about 45% of maximal light intensity). If the
animal failed to flick its tail within 10 s (cut-off point), the tail was
removed from the coil to prevent damage to the skin (Haghparast
et al., 2012; Ebrahimzadeh and Haghparast, 2011; Parvishan et al.,
2011). TFLs (sec) are expressed either as raw data or percentage of
maximal possible effect (%MPE)whichwas calculated from the following
formula:
%MPE ¼ Post drug latency secð Þ−Baseline latency secð Þ
Cut off value secð Þ−Baseline latency secð Þ  100
2.6. Experimental design
In this study, there were three control groups including intact,
sham-operated and saline groups (n = 6 in each group) for deter-
mining the baseline TFLs, surgical manipulation and microinjection
volume effects, respectively. To evaluate the involvement of OX1
receptors within the VTA and NAc in antinociceptive responses
induced by LH stimulation, tail-flick test was performed as a model
of acute pain. In all above control and experimental groups, TFLs
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istrations (Safari et al., 2009).2.6.1. Dose–response effects of carbachol microinjected into the LH on
tail-flick test
In these experiments, a dose–response relationship for car-
bachol as a LH chemical stimulation agent on tail-flick was
established. Different doses of carbachol (125 and 250 nmol/0.5 μl
saline; n = 6 in each group) microinjected into the LH, were tested
(Holden and Naleway, 2001). Control animals received saline (n =
6).2.6.2. Effects of intra-VTA administration of OX1 receptor antagonist,
SB334867 on antinociception induced by intra-VTA administration
of carbachol
To test the role of OX1 receptors within the VTA in the LH
stimulation-induced antinociception, different doses of SB334867 (0.3,
1, 3 and 10 nmol/0.3 μl DMSO; n = 5–6 in each group)were unilaterally
injected into the VTA, 5 min prior to effective dose of intra-LH carbachol
administration, which was followed by a tail-flick test after 5 min. In the
vehicles group (n = 6), DMSO was microinjected into the NAc and
2 min later animals received saline in the LH.2.6.3. Effects of intra-NAc administration of OX1 receptor antagonist,
SB334867 on antinociception induced by intra-VTA administration
of carbachol
To test the role of intra-accumbal OX1 receptors in the LH
stimulation-induced antinociception, different doses of SB334867
(0.3, 1, 3 and 10 nmol/0.5 μl DMSO; n = 6 in each group) were
unilaterally injected into the NAc, 5 min prior to infusion of effective
dose of intra-LH carbachol. In the vehicles group (n = 6), DMSO was
microinjected into the VTA and 2 min later, animals received saline in
the LH.2.7. Histology
After performing the test, the animals were deeply anesthetized
with Ketamine and Xylazine. Then, they were transcardially perfused
with 0.9% saline and 10% formalin solution. The brains were removed,
blocked and cut coronally in 50 μm sections through the cannulae
placements. The neuroanatomical locations of cannulae tips were
confirmed using Paxinos and Watson rat brain atlas (Paxinos and
Watson, 2007). Only the animals with correct cannulae placements
were included in the data analysis.2.8. Statistics
The obtained results are expressed as mean ± SEM (standard error
of mean). The mean TFLs in all groups were subjected to one-way and/
or two-way ANOVA followed by protected Tukey's or Bonferroni's test
for multiple comparisons, respectively. The mean maximal possible
effect (%MPE) of drugs, as an analgesic index, was subjected to un-
paired student t-test for comparison of two independent groups at
time set intervals. In order to evaluate the nociceptive responses, area
under the curve (AUC) was calculated as raw pain scores × time by
linear trapezoidal method and a single value was used in statistical
analyses. The calculated AUC and pain score values in all groups
were subjected to one-way and/or two-way ANOVA followed by
protected Tukey's or Bonferroni's test for multiple comparisons,
respectively. P-value less than 0.05 was considered to be statistically
significant.3. Results
3.1. Dose–response effects of chemical stimulation of the lateral
hypothalamus by carbachol on tail-flick test as an animalmodel of acute pain
In this set of experiments,we examined the dose–response effects of
two doses of carbachol (125 and 250 nmol/rat) microinjected into the
LH for the chemical stimulation of LH on TFLs in the rats. Two-way
ANOVA for repeated measures over time followed by Bonferroni's
test for %MPEs indicated a significant differences in antinociceptive
responses to carbachol microinjected into the LH alone compared
to those of respective saline-treated group [treatment effect: F(2,
70) = 31.33, P b 0.0001; time effect: F(4, 70) = 0.5388, P = 0.7077;
interaction: F(8, 70) = 0.4991, P = 0.8529; Fig. 1A]. Moreover, as
shown in Fig. 1B, one-wayANOVA followed byNewman–Keulsmultiple
comparison test showed that there are significant differences in mean
AUC calculated values for %MPEs [F(2, 16) = 22.4, P b 0.0001] among
the experimental (different doses of carbachol) and control (saline)
groups. However, there was no significant difference in AUC calculated
values for %MPEs as an index of antinociception between these two
doses of carbachol. Therefore, we used the lower dose of carbachol,
125 nmol/rat, in the other experimental groups.
3.2. Effect of intra-VTA administration of OX1r antagonist SB334867 on
LH stimulation-induced antinociception
To evaluate the receptor specific response ofOX1 receptors in theVTA,
we examined the effect of intra-VTA administration of SB334867 as a
selective OX1r antagonist on LH stimulation-induced antinociception by
carbachol. Two-way ANOVA for repeated measures over time followed
by Bonferroni's test for %MPEs indicated a significant differences
in antinociceptive responses to carbachol microinjected into the LH
alone or when carbachol was concurrently administrated into the LH
following different doses of intra-VTA SB334867 compared to those of
respective saline-treated group [treatment effect: F(6, 160) = 31.17,
P b 0.0001; time effect: F(4, 160) = 1.368, P = 0.2475; interaction:
F(24, 160) = 0.8157, P = 0.7130; Fig. 2A]. However, there are no sig-
nificant differences in %MPEs at any time intervals among the control
and experimental groups. Moreover, as shown in Fig. 2B, one-way
ANOVA followed by Newman–Keuls multiple comparison test showed
that there are significant differences in mean AUC calculated values
for %MPEs [F(6, 32) = 12. 39: P b 0.0001] among the experimental
and control (vehicles) groups. Data obtained in this experiment show
that intra-VTA administration of SB334867 as an OX1r antagonist
dose-dependently prevents LH stimulation-induced antinociception
in rats. Intra-VTA administration of SB334867 (1, 3 and 10 but
not 0.3 nmol/rat) significantly reduced %MPEs as an index for
antinociception in comparison with DMSO respective control group
that received carbachol (125 nmol/rat) only into the LH. On the other
hand, administration of maximum dose of SB334867 (10 nmol/rat)
alone into the VTA could not affect the baseline TFLs (or %MPEs) at
time set intervals and/or mean AUC calculated values compared to
vehicles group (Fig. 2B).
3.3. Effect of intra-accumbal administration of SB334867 on antinociception
induced by carbachol microinjected into the LH
In this set of experiments, we evaluated the dose–response
effects of intra-NAc administration of selective OX1r antagonist
SB334867 on the antinociceptive response of carbachol microinjected
into the LH during a 60-min period. Although two-way ANOVA
followed by Bonferroni's test [treatment effect: F(6,160) = 41.53,
p b 0.0001; time effect F(4,160) = 1.218, P = 0.3053; interaction F
(24,160) = 0.5021, P b 0.9750] revealed that there are significant
differences in %MPE values among the experimental and control groups
in Fig. 3A, there were no significant differences in %MPEs at any time
Fig. 1. Effect of unilateral administration of different doses of carbachol in the lateral hypothalamus (LH) on tail-flick latencies in the rats. (A) Maximal possible effect of two doses of
carbachol at 5, 15, 30, 45 and 60 min after microinjection and (B) area under the curves (AUCs) calculated for %MPEs in 60-min period in tail-flick test as a model of acute pain shown
in A. Animals received carbachol (125 and 250 nmol/0.5 μl saline) or saline as a vehicle into the LH. Each point shows the mean ± SEM for 5–6 rats. *P b 0.05, **P b 0.01, ***P b 0.001
different from the saline control group.
Fig. 2. Effect of unilateral microinjection of different doses of SB334867, an OX1 receptor
antagonist, in the ventral tegmental area (VTA) on antinociception induced by chemical
stimulation of the lateral hypothalamus (LH) as (A) maximal possible effect at 5, 15, 30,
45 and 60 min after microinjection and (B) area under the curves (AUCs) calculated for
%MPEs in 60-min period in tail-flick test as a model of acute pain shown in A. Animals
received SB334867 (0.3, 1, 3 and 10 nmol/0.5 μl DMSO) or DMSO as a vehicle 5 min before
intra-LH administration of carbachol (125 nmol/rat). Each point shows the mean ± SEM
for 6–8 rats. *P b 0.05, **P b 0.01, ***P b 0.001 different from the control (vehicle) group.
† P b 0.05, †† P b 0.01, ††† P b 0.01 different from the respective DMSO group.
196 S. Sadeghi et al. / Pharmacology, Biochemistry and Behavior 105 (2013) 193–198intervals. Nonetheless, one-way ANOVA followed by Newman–Keuls
multiple comparison test [F (6, 32) = 12. 39: P b 0.0001] showed that
there are significant differences in mean AUC calculated values for
%MPEs among the experimental and control (vehicles) groups. However,
as shown in Fig. 3B, intra-VTA administration of SB334867 only at
high doses (3 and 10 nmol/rat) could significantly reduced mean AUC
(or %MPEs) in comparison with DMSO respective control group that
received carbachol (125 nmol/rat) into the LH.Moreover, administration
of maximum dose of SB334867 (10 nmol/rat) alone into the NAc could
not affect the AUC calculated values compared to vehicles group.
On the other hand, we tried to set the AUC of the control (animals
that received only 125 nmol carbachol in the LH) to 100%, and represent
the remaining AUCs (animals that received different doses of SB334867
in the NAc or VTA) as % changes in their responses (Fig. 4). This figure,
a log dose–response curve for carbachol in the LH and SB334867 as an
OX1 receptor antagonist in either the NAc or VTA, shows that the 50%
effective dose (ED50) value of SB334867 on intra-LH carbachol-
induced antinociception in the VTA (1.13 nmol) is less that in the NAc
(1.89 nmol). However, there was no significant difference between
these two ED50 values in this study.
4. Discussion
The purpose of this study was to evaluate the involvement of
orexin-1 receptors within the VTA and NAc in the antinociceptive
responses induced by LH stimulation in the rat. The major findings are:
(1) administration of different doses of carbachol into the LH produced
antinociceptive responses in tail-flick test, (2) administration of an OX1
receptor antagonist (SB334867) into the VTA dose-dependently blocked
the carbachol-induced antinociception and (3) unilateral intra-accumbal
microinjection of SB334867 inhibited antinociceptive responses induced
by intra-LH carbachol. Previous studies have shown that the stimulation
or inactivation of LH produces antinociception (Tasker et al., 1987;
Behbehani et al., 1988; Safari et al., 2009). The results in the first set of
experiments are in agreement with previous studies, but we used two
different doses of carbachol; although there were no significant differ-
ences in antinociceptive effects, the lower dose was the most effective
dose.
Orexinergic projections originated from the LH innervate many
brain regions like the VTA, NAc, amygdale and prefrontal cortex
(PFC). In the VTA, orexin receptors have been settled on both dopami-
nergic and GABAergic neurons. Activation of orexin receptors in the
Fig. 4. A log dose–response curve for carbachol in the lateral hypothalamus (LH) and
SB334867 as an OX1 receptor antagonist in either the nucleus accumbens (NAc)
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the NAc and PFC through its projections (Sharf et al., 2010). Previous
research studies have demonstrated that these projections have impor-
tant roles in the reward circuitry (Taslimi et al., 2011). Some researchers
have shown that the dopaminergic neurons in the VTA involve in
both endogenous opioid- and morphine-induced antinociception
(Altier and Stewart, 1993). Moreover, it has been shown that lesion of
the VTA dopaminergic neurons affects on hyperalgesic responses and
could increase self-mutilating behaviors after de-afferentation (Saade
et al., 1997). Previous studies reported that stress-induced analgesia in
the formalin test is mediated by SP and opioid receptors in the VTA
(Altier and Stewart, 1998). Several studies have also shown that analge-
sia induced by intra-VTA tachykinins and intra-NAc amphetamine in-
creases dopamine release in the NAc (Altier and Stewart, 1998).
Additionally, it has been found that analgesic effect of injection of the
SP analogue, DiMe-C7, into the VTA attenuates by the infusion of D1 re-
ceptor antagonist SCH23390 into the NAc (Altier and Stewart, 1998).
On the other hand, there are some reasons to believe that lesions of
the substantia nigra by 6-hydroxydopamine block analgesia induced by
D-amphetamine and morphine in the formalin test (Morgan andor ventral tegmental area (VTA). In this figure we tried to set the AUC of the control
(animals that received only 125 nmol carbachol in the LH) to 100%, and represent
the remaining AUCs (animals that received different doses of SB334867 in the NAc or
VTA) as a % of that to generate an effective dose 50% (ED50) of SB334867 in the VTA
(1.13 nmol) or NAc (1.89 nmol).
Fig. 3. Effect of unilateral microinjection of different doses of SB334867, an OX1 receptor
antagonist, in the nucleus accumbens (NAc) on antinociception induced by chemical
stimulation of the lateral hypothalamus (LH) as (A) maximal possible effect at 5, 15, 30,
45 and 60 min after microinjection and (B) area under the curves (AUCs) calculated for
%MPEs in 60-min period in tail-flick test as a model of acute pain shown in A. Animals
received SB334867 (0.3, 1, 3 and 10 nmol/0.5 μl DMSO) or DMSO as a vehicle 5 min before
intra-LH administration of carbachol (125 nmol/rat). Each point shows the mean ± SEM
for 6–8 rats. *P b 0.05, **P b 0.01, ***P b 0.001 different from the control (vehicle) group.
† P b 0.05, ††† P b 0.01 different from the respective DMSO group.Franklin, 1990, 1991). Ghalandari-Shamami et al. (2011) showed that
the NAc plays an important role in modulation of pain. This study sup-
ports the involvement of the NAc in the antinociception induced by
intra-BLA administration of cannabinoid receptor agonist in tail-
flick test (Ghalandari-Shamami et al., 2011). Also, it has been
shown that antinociception induced by intra-VTA DiMe-C7 was
decreased by intra-NAc infusions of the mixed dopamine receptor an-
tagonist flupenthixol (Altier and Stewart, 1998). So, our findings in
this study suggest that orexin-1 receptors in the VTA and NAc involve
in the antinociception induced by LH stimulation, and LH orexinergic
projections to these areas act, in part, through orexin-1 receptorswithin
the VTA and NAc in pain modulation. On the other hand, it has been
shown that the distribution of orexin receptors in these areas isn't the
same, and the quantity of OX1 receptors in the VTA is more than that
in the NAc (Sharf et al., 2010). Our results had been matched
with previous findings because we observed the attenuation of the
antinociceptive responses induced by LH-stimulation by blocking the
OX1 receptors within the VTA, this attenuation was stronger than that
in the NAc. In conclusion, it seems that the VTA orexinergic receptors
are more effective on modulation of the pain descending inhibitory
system than those receptors in the NAc. Additionally, we also suggest
that among the brain areas which are associated with antinociceptive
effects induced by LH-stimulation, VTA could be chosen as the first
region involves in this phenomenon and the NAc as the second.
Nevertheless, it is necessary that we extend our investigations in
the future.
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